Source legit

Growth hormone releasing peptides protocol log

Sermorelin Peptide in United States (USA)

Mechanism, dose window, half-life, stack pairing, sourcing pathway. The sermorelin entry, plus adjacent GHRPs and GHRH analogs adults actually run.

Start your consultation

Sermorelin is a 29-amino-acid synthetic peptide that mirrors the first 29 residues of natural growth hormone releasing hormone (GHRH), the hypothalamic neurohormone that drives anterior pituitary somatotrophs to secrete endogenous growth hormone. When administered subcutaneously, sermorelin binds the GHRH receptor (GHRHR) on the pituitary surface, triggers a Gs-coupled adenylyl-cyclase cascade, and elicits a brief, physiological pulse of native human growth hormone. The downstream signal feeds the hepatic IGF-1 axis intact, with somatostatin and IGF-1 negative feedback loops preserved. That feedback preservation is the defining clinical argument for the molecule and the reason it remains a touchstone within the broader GH-axis peptide category.

Positioning sermorelin requires understanding the family it belongs to. The growth-hormone-axis peptide landscape splits into two structural and pharmacological branches: GHRH analogs that act on GHRHR (sermorelin, CJC-1295, tesamorelin), and growth hormone releasing peptides (GHRPs) that act on the ghrelin receptor (GHS-R1a) — ipamorelin, hexarelin, GHRP-2 and GHRP-6. Sermorelin sits at the structural origin of the GHRH-analog branch. It is not a synthetic mimic of a separate signaling system the way GHRPs are; it is, literally, the active fragment of the hormone the hypothalamus already produces, manufactured outside the body and delivered into the subcutaneous space.

Why 29 amino acids is enough — structural rationale

Natural human GHRH circulates as a 44-amino-acid peptide. The receptor-binding pharmacophore, however, sits almost entirely within the N-terminal portion of the chain. Crystallographic and structure–activity work performed over four decades has consistently shown that residues 1 through 29 contain the entire stretch required for full agonist activity at GHRHR. Residues 30 through 44 contribute to plasma stability and certain conformational nuances, but they are not required for receptor docking or for activation of the Gs-coupled cascade that releases growth hormone from secretory granules.

The N-terminal residues — particularly the tyrosine at position 1 and the aspartate at position 3 — anchor the peptide into the receptor’s extracellular domain. The middle helical region (roughly residues 6–22) provides the amphipathic alpha-helix that orients the molecule against the transmembrane face. The C-terminal portion of the 1–29 fragment closes the binding pocket. Truncate the peptide any shorter and you progressively lose binding affinity; extend it to the full 44 and you gain a degradation-prone tail without measurable potency gain.

This is why sermorelin is, in molecular terms, the “minimal active fragment” of GHRH. It is sometimes labeled GHRH(1-29)-NH2 in the literature, the amide referring to the C-terminal amidation that further stabilizes the helical conformation. Compounders, prescribers, and patients sometimes assume sermorelin is a “weaker” version of GHRH because it is shorter. The opposite is closer to the truth: the missing 15 residues were never doing the receptor work in the first place. What sermorelin loses relative to native GHRH is plasma persistence, not pharmacological signal.

GHRH analogs vs growth hormone releasing peptides

The cleanest way to categorize the modern GH-axis peptides is by which receptor they engage. Sermorelin, CJC-1295, and tesamorelin all bind GHRHR. They differ in stability and dosing cadence but share a mechanism: they tell the pituitary, in the same molecular language the hypothalamus uses, to release a GH pulse. CJC-1295 is a tetrasubstituted GHRH(1-29) analog with amino-acid substitutions at positions 2, 8, 15, and 27 that resist DPP-IV cleavage. In its DAC (drug affinity complex) form, a maleimide tail binds covalently to albumin, extending the half-life from minutes to days. Tesamorelin is a 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid cap that blocks aminopeptidase degradation; it is FDA-approved (Egrifta) for HIV-associated lipodystrophy.

Ipamorelin, hexarelin, GHRP-2, and GHRP-6 are different molecules entirely. They are small synthetic peptides — five or six amino acids — that bind GHS-R1a, the ghrelin receptor. They mimic the GH-releasing action of acylated ghrelin rather than GHRH. They engage a separate Gq-coupled pathway in the pituitary that amplifies, rather than initiates, GH release. Ipamorelin is the cleanest GHRP because it is selective for GHS-R1a in pituitary tissue without meaningful cortisol, prolactin, or aldosterone stimulation, which earlier-generation GHRP-6 produced through off-target effects.

The mechanistic implication is that GHRH analogs and GHRPs are synergistic, not redundant. The pituitary somatotroph has two independent triggers, and activating both simultaneously produces a larger pulse than activating either alone — published synergy data report GH release several-fold greater for paired administration than for either peptide at matched dose. This is why CJC-1295 and ipamorelin are frequently stacked. Sermorelin, by virtue of being the canonical GHRH analog, is the original anchor of the GHRH side of that synergy framework, and its molecular footprint is the closest of any compounded peptide to what the hypothalamus itself releases each night.

Half-life, dosing cadence, and why nightly subQ is the format

Sermorelin’s plasma half-life in adults is approximately 10 to 20 minutes after subcutaneous administration, with most published clearance values clustering near 11 to 12 minutes. The peptide is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) and other circulating aminopeptidases that cleave it at the N-terminus, destroying receptor-binding capacity. Total body clearance falls in the range of 2.4 to 2.8 liters per minute. There is no sustained plasma reservoir, no albumin tethering, and no enzymatic shielding — the molecule is built to be transient.

That short half-life is not a flaw; it is what allows sermorelin to track the body’s endogenous GH rhythm. Physiological GH release is pulsatile, with the largest secretory burst occurring in the first hour of slow-wave sleep. A subcutaneous bolus of sermorelin given just before bedtime overlaps with that natural window, amplifies the nocturnal pulse, and is cleared from the circulation before morning. Daytime IGF-1 feedback and somatostatin tone remain intact, which is the pharmacological argument for sermorelin over continuous-exposure agents.

Typical adult dosing falls in the 200 to 1000 microgram range delivered subcutaneously once nightly, with most clinical protocols initiating at 200 to 300 mcg and titrating upward to a clinical and IGF-1 response. Higher end-of-range doses (closer to 1000 mcg) appear in older protocols and in patients with blunted pituitary reserve; most contemporary compounded prescriptions sit between 200 and 500 mcg nightly. Injection sites are rotated through the abdomen or thigh, the reconstituted vial is kept refrigerated, and bedtime administration is consistently recommended to align with circadian GH secretion.

The compounded prescription pathway and 503A/503B context

Sermorelin was originally FDA-approved in 1997 as Geref, indicated for diagnostic evaluation and treatment of pediatric growth hormone deficiency. The manufacturer discontinued commercial production in 2008 for business reasons unrelated to safety or efficacy. The molecule itself was never withdrawn for clinical concerns, and the API remained available to the compounding channel.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may compound a drug for an individually identified patient using a bulk drug substance that meets one of several listed criteria, including being a component of an FDA-approved drug. Because sermorelin acetate was the API of Geref, it qualifies for 503A compounding by licensed pharmacies operating against patient-specific prescriptions. The FDA continues to evaluate the 503A bulks list, and sermorelin’s regulatory standing in that framework has been the subject of ongoing review. Compounded sermorelin is not an FDA-approved drug product — it is a patient-specific preparation prescribed by a licensed clinician, dispensed by a licensed compounding pharmacy, and supplied with a beyond-use date rather than an expiration date.

This distinction matters clinically. 503A preparations are not interchangeable with mass-produced pharmaceuticals; they are not manufactured under cGMP at the same scale as 503B outsourcing facilities, and they require an individualized prescriber-patient-pharmacist relationship. Patients seeking sermorelin work through a clinic that handles screening, prescription, and follow-up, with the pharmacy filling the order rather than dispensing an off-the-shelf inventory product.

Who responds, who doesn’t, what the screening looks like

Sermorelin requires functioning pituitary somatotrophs. Patients with intact, age-related decline in GH secretion typically respond. Patients with structural pituitary pathology, prior pituitary surgery, radiation exposure to the sellar region, or panhypopituitarism may not — the molecule needs a target cell that can still secrete GH on command. Baseline screening usually includes a comprehensive metabolic panel, lipid panel, fasting insulin, IGF-1, a full thyroid panel, free testosterone in men, and vitamin D. Untreated hypothyroidism blunts the GH response and is corrected before therapy begins.

Sermorelin is contraindicated in pregnancy, in patients with active malignancy, and in those with untreated severe hepatic or renal disease. Quarterly IGF-1 monitoring is standard during therapy to confirm physiological response and to keep levels within the upper-normal adult range rather than into supraphysiological territory. Patients considering pregnancy discontinue at least 8 to 12 weeks in advance and confirm IGF-1 has returned to baseline before conception.

Sermorelin therapy is delivered locally through compounding pharmacies and prescribing clinics that handle the screening labs, the prescription, and the follow-up monitoring. Availability, intake protocols, and pharmacy partnerships vary by state and metro area. Browse the directory below to find providers and compounding resources for sermorelin peptide therapy near you.

States in the Northeast

States in the Midwest

States in the South

States in the West

Major cities across the United States

Sermorelin, profile entry in the United States, USA

A 29 amino acid GHRH analog that binds the same pituitary receptor as endogenous growth hormone releasing hormone. Triggers a physiologic pulse of growth hormone in the body's own pattern, while the natural negative feedback loop stays intact. Approved branded form discontinued. For adults across the United States, USA, modern administration is compounded, prescription only, from US 503A and 503B pharmacies.

Dark laboratory shelf with sermorelin peptide vials lit by a thin lime accent

Mechanism

Binds pituitary GHRH receptor, triggers pulsatile GH release. Feedback loop preserved.

Dose window

100 to 500 mcg subcutaneous nightly. Most US telehealth protocols sit at 200 to 300 mcg.

Cycle length

12 weeks standard. Re-evaluate IGF-1 at week 12. Off-cycle 4 to 8 weeks if continuing.

Lab markers

IGF-1, fasting glucose, HbA1c, lipids, basic metabolic panel.

Common stack

Sermorelin GHRH plus ipamorelin GHRP for synergistic pulse amplification.

Side effect floor

Injection site redness, transient flush, occasional headache. Hypoglycemia screened.

Adjacent peptides commonly stacked

Sermorelin rarely runs alone in serious protocols. The two adjacent classes worth understanding are GHRPs, which amplify GH pulse amplitude, and longer half-life GHRH analogs, which extend the pulse window. The table below summarizes the field. None of these are sold legally without prescription in the US.

Molecular wireframe visualization of growth hormone releasing peptides on a dark screen
PeptideClassHalf lifeTypical role
SermorelinGHRH analog10 to 20 minRestore natural overnight pulse
TesamorelinGHRH analog, modified26 min in serumStronger pulse, FDA approved for HIV lipodystrophy
CJC 1295 with DACGHRH analog, long actingDays, not minutesSustained elevation, loses pulsatility
IpamorelinGHRP, selective2 hoursPulse amplification, minimal cortisol or prolactin
GHRP 2GHRP1 to 2 hoursPulse amplification, mild appetite increase
HexarelinGHRPApprox 1 hourStrong pulse but blunts response over time, rarely used long term

The cycle protocol

A standard 12 week sermorelin run looks like the schedule below. Adjust dose by clinician, not by self-titration. The five-on-two-off cadence reduces tachyphylaxis at the pituitary GHRH receptor over a long cycle.

WeekDoseCadenceLab checkNotes
1 to 4200 mcg5 on, 2 offBaseline IGF-1 doneSleep depth shifts first. Hold steady.
5 to 8200 to 300 mcg5 on, 2 offNone mid cycleSkin, hair, energy. Training recovery up.
9 to 12300 mcg5 on, 2 offFollow up IGF-1 at week 12Body composition window. Reassess.
Week 13Pause or maintainClinician callCompare IGF-1 to baselineDecide hold, lower, or cycle off 4 to 8 weeks.

Sourcing pathway in the United States

There are two channels for sermorelin in the US. One is legal, clinical, and traceable. The other is not, and is sold under a research-only label that buyers routinely ignore. The difference matters for purity, dose accuracy, and personal legal exposure.

Dark lab interface dashboard showing IGF-1 and protocol tracking data

Clinical pathway

Compounded prescription

  • Online consultation with a licensed clinician in your state
  • Baseline IGF-1 plus metabolic panel ordered
  • Prescription dispensed by a 503A or 503B compounding pharmacy
  • Sterile vial, accurate concentration, traceable batch
  • Sharps kit, dosing protocol, follow-up labs

View licensed provider

Research-only pathway

Grey market peptide vendor

  • Sold as research chemical, not for human consumption
  • No clinician oversight, no prescription, no liability
  • Purity and dose vary by batch and supplier
  • No medical record, no lab follow-up
  • Federal grey area for buyer, frank illegal for some sellers

Not recommended for any adult running protocols seriously.

Self-tracking log, what to measure

Sermorelin works on a slow curve. The signal arrives over weeks, not days, and shows up unevenly across markers. The tracking spec below catches the typical response without over-instrumenting.

Top down view of lab equipment, micropipettes and small vials on a matte black surface

  • Sleep depth, weeks 1 to 4

    Wearable deep sleep minutes, subjective restfulness on waking. Most consistent first signal.

  • Morning energy, weeks 1 to 4

    Subjective on a 1 to 10 scale at the same time each morning. Daily, no trend smoothing the first month.

  • Training recovery, weeks 4 to 8

    Time to feel ready for the next session after a hard lift or run. Notes on DOMS duration.

  • Body composition, weeks 8 to 12

    Same day of week, same time of day, same equipment. Waist circumference and weight at minimum. DEXA if possible at baseline and end.

  • IGF-1, week 12

    Follow up draw. Compare to baseline. This is the only objective biochemical signal the protocol moves predictably.

  • Fasting glucose, monthly

    Safety marker. GH downstream can shift insulin sensitivity. Flag any sustained rise.

Source it through a US licensed clinic in the United States, USA

Compounded sermorelin from a registered pharmacy, after a real consultation and lab with a US-licensed clinician. Refund if the clinician says no.

Start your consultation